TBPH: Theravance Kompaniya qiymatining sof foydaga nisbati

Theravance Biopharma Inc (TBPH) korporativ emblemasi va logotipi

Theravance Biopharma (TBPH) kompaniyasining o'rtacha og'irlikli P/E ko'rsatkichi joriy bozor bahosini aks ettiradi, bunda 16.70 indikatori ushbu metrikaning holatini ifodalaydi. Ushbu tendentsiya Theravance Biopharma kompaniyasining respirator va gastrointestinal terapiyalarning B2B segmentiga e'tibor qaratganligi bilan bog'liq. Istiqlbollar minimal nojo'ya ta'sirlarga ega yuqori aniqlikdagi molekulalarning ishlab chiqilishiga tayanadi. Biroq, o'sish trayektoriyasi aktivlarni qayta tuzatgandan so'ng boshqaruvning R&D xarajatlarini optimallashtirish qobiliyatiga bog'liq.

TBPH Theravance Corp: Narx-foyda koeffitsiyenti 04.07.2022 - 10.10.2026 oraligʻida

Theravance Biopharma Inc (TBPH) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- narx va narxlar bo'yicha konsensus prognoz:
Kompaniyaning har tomonlama tahlili:Theravance - TBPH
Theravance Biopharma, Inc. yetakchi tovari

Theravance Biopharma (TBPH) kompaniyasining P/E koeffitsiyenti sof foydaning bir birligi xarajatini aks ettiradi, bu esa kompaniyaning joriy bozor P/E koeffitsiyenti aktivning haqiqiy daromadlariga nisbatan qanchalik qimmat baholanganini aniqlash imkonini beradi. Ushbu ko'rsatkich, respirator dori vositalariga bo'lgan no-tsiklik talab bilan birgalikda, biznesning makroiqtisodiy zarbalarga yuqori chidamliligini tasdiqlaydi va investorlarga hatto bozor tebranishlari davrida ham barqaror fundamental tayanchni taqdim etadi.

Raqobatdosh kompaniyalar

HLN: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Jyong Biotech Limited MENS|Ligand (LGND) - Kapitalizatsiyaning foydaga nisbati|AMRX: Narx-foyda koeffitsiyenti|Perrigo - Bozor narxining sof foydaga nisbati|ALVO: P/E multiplikatori|Liquidia Technologies - Kompaniya qiymatining sof foydaga nisbati|GLPG (Galapagos N.V.) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati anipharmaceuticals.com ANIP|Narxning foydaga nisbati MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Pacira BioSciences, Inc. PCRX|P/E multiplikatori ARS Corp SPRY|AQST - Narxning foydaga nisbati|scPharmaceuticals (SCPH) - Narx-foyda koeffitsiyenti|TECX: P/E multiplikatori|Narx-foyda multiplikatori TNXP|Narxning foydaga nisbati China SXT Pharmaceuticals, Inc.|EPRX: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori BHST|EXOZ - Kapitalizatsiyaning foydaga nisbati|P/E multiplikatori ORMP (oramed.com)|P/E multiplikatori enterabio.com ENTX|HYFT - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati ABVC BioPharma, Inc ABVC|CPIX: P/E multiplikatori|Quantum BioPharma Ltd - Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti FGEN|Telomir Pharmaceuticals, Inc. - Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori RANI|SNYR (Synergy CHC) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Rallybio RLYB|Lexaria Bioscience (LEXX) - Kapitalizatsiyaning foydaga nisbati|PULM - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Pheton Holdings PTHL|APM (Aptorum) - Narx-foyda koeffitsiyenti|Lyra Therapeutics, Inc. (LYRA) - P/E multiplikatori|IBO (impactbiomedinc.com) - P/E multiplikatori|TNFA (TNF Pharmaceuticals) - Bozor narxining sof foydaga nisbati|Narxning foydaga nisbati cbdmd.com (YCBD)|Biznesning o‘zini qoplash muddati PainReform Ltd|P/E multiplikatori CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Kapitalizatsiyaning foydaga nisbati|OPTN - Narxning foydaga nisbati|Pieris Pharmaceuticals - Bozor narxining sof foydaga nisbati|PROC (Procaps Group) - Narx-foyda koeffitsiyenti|PTPI - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Qilian International Holding Group Limited|SLRN: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti TFFP (TFF Pharma)